Semaglutide was associated with a lower rate of bone fractures and greater reductions in body mass index among adults with type 2 diabetes, according to a retrospective analysis presented at the Endocrine Society’s ENDO 2026 meeting in Chicago.
Researchers reported the findings on Sunday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, according to an Endocrine Society press release.
The analysis, which used electronic health records, compared adults with type 2 diabetes who received semaglutide (26,324 patients) with a control group (33,555 patients) treated with dulaglutide or oral weight-loss therapies including phentermine/topiramate and bupropion/naltrexone. The semaglutide group had 794 recorded fractures versus 1,045 in the comparison group, and the researchers said semaglutide was associated with a larger reduction in body mass index.
The researchers described the work as a retrospective cohort study and said the results suggest semaglutide was associated with about a 15% reduction in fractures compared with the other therapies.
“Bone fractures are painful, expensive and can seriously affect quality of life — especially as people get older,” lead researcher Jairo Noreña said in the press release, adding that he hoped the findings would encourage monitoring of bone health in weight-loss programs.
The authors said prospective studies are needed to confirm the findings.
